Redmile Group LLC Acquires New Position in BioNTech SE (NASDAQ:BNTX)

Redmile Group LLC bought a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 154,456 shares of the company's stock, valued at approximately $18,345,000. Redmile Group LLC owned approximately 0.06% of BioNTech at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. GAMMA Investing LLC increased its position in shares of BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company's stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock worth $43,000 after purchasing an additional 252 shares in the last quarter. Planning Capital Management Corp increased its holdings in BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company's stock valued at $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. raised its stake in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company's stock worth $155,000 after buying an additional 1,562 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

Analyst Ratings Changes

A number of research firms have recently commented on BNTX. Jefferies Financial Group upgraded BioNTech from a "hold" rating to a "buy" rating and increased their price objective for the company from $96.00 to $150.00 in a report on Tuesday, September 17th. Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They issued a "buy" rating and a $130.00 price target on the stock. Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. The Goldman Sachs Group upgraded shares of BioNTech from a "neutral" rating to a "buy" rating and upped their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Finally, HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Stock Performance

BNTX traded up $4.14 on Thursday, hitting $118.84. 678,438 shares of the company traded hands, compared to its average volume of 812,013. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a 50 day moving average of $113.81 and a 200-day moving average of $99.23. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $28.49 billion, a PE ratio of -56.59 and a beta of 0.22.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $514.08 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The company's quarterly revenue was up 38.9% compared to the same quarter last year. Sell-side analysts anticipate that BioNTech SE will post -3.72 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.